Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
Go back to Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)| (NASDAQ: ABUS) | Delayed: 5.01 +0.01 (0.20%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.00 | 52 Week High | $5.88 | |||
| Open | $5.02 | 52 Week Low | $2.65 | |||
| Day High | $5.05 | P/E | N/A | |||
| Day Low | $5.00 | EPS | $0.00 | |||
| Volume | 10,494,037 | |||||
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 251.65 +7.33 (3.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $244.32 | 52 Week High | $109.10 | |||
| Open | $246.86 | 52 Week Low | $31.38 | |||
| Day High | $255.51 | P/E | N/A | |||
| Day Low | $244.13 | EPS | $-1.45 | |||
| Volume | 1,131,820 | |||||
